KRYS (STOCKS)
Krystal Biotech, Inc. Common Stock
$267.970000
-2.030000 (-0.75%)
Prev close: $270.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Krish S. Krishnan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,833.35M
- Employees
- 275
- P/E (TTM)
- 39.48
- P/B (TTM)
- 6.46
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.70 | $1.44 | +0.2633 | +18.33% |
|
Sep 2025 (Q3)
|
$2.66 | $1.11 | +1.5527 | +140.22% |
|
Jun 2025 (Q2)
|
$1.29 | $1.15 | +0.1397 | +12.14% |
|
Mar 2025 (Q1)
|
$1.20 | $1.39 | -0.1936 | -13.89% |
Financial Statements
| Revenues | $389.13M |
| Benefits Costs and Expenses | $199.66M |
| Costs And Expenses | $199.66M |
| Operating Expenses | $227.84M |
| Selling, General, and Administrative Expenses | $146.74M |
| Research and Development | $58.05M |
| Other Operating Expenses | $23.05M |
| Operating Income/Loss | $161.30M |
| Income/Loss From Continuing Operations After Tax | $204.83M |
| Income/Loss From Continuing Operations Before Tax | $189.47M |
| Income Tax Expense/Benefit | -$15.36M |
| Income Tax Expense/Benefit, Current | $11.92M |
| Income Tax Expense/Benefit, Deferred | -$27.28M |
| Net Income/Loss | $204.83M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $204.83M |
| Net Income/Loss Available To Common Stockholders, Basic | $204.83M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $7.08 |
| Diluted Earnings Per Share | $6.84 |
| Basic Average Shares | 28,944,000 |
| Diluted Average Shares | 29,951,000 |
| Assets | $1.33B |
| Current Assets | $1.02B |
| Cash | $827.80M |
| Inventory | $40.48M |
| Other Current Assets | $156.33M |
| Noncurrent Assets | $309.19M |
| Fixed Assets | $150.78M |
| Other Non-current Assets | $158.42M |
| Liabilities | $114.23M |
| Current Liabilities | $102.94M |
| Accounts Payable | $3.24M |
| Other Current Liabilities | $99.70M |
| Noncurrent Liabilities | $11.29M |
| Equity | $1.22B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.22B |
| Liabilities And Equity | $1.33B |
| Net Cash Flow From Operating Activities | $200.87M |
| Net Cash Flow From Operating Activities, Continuing | $200.87M |
| Net Cash Flow From Investing Activities | -$58.42M |
| Net Cash Flow From Investing Activities, Continuing | -$58.42M |
| Net Cash Flow From Financing Activities | $8.71M |
| Net Cash Flow From Financing Activities, Continuing | $8.71M |
| Exchange Gains/Losses | $286.00K |
| Net Cash Flow | $151.44M |
| Net Cash Flow, Continuing | $151.15M |
| Comprehensive Income/Loss | $206.16M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $206.16M |
| Other Comprehensive Income/Loss | $206.16M |